Media coverage
15
Media coverage
Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet Genmab Country/Territory Denmark Date 3/06/24 URL ct.moreover.com/?a=53962914680&p=1gw&v=1&x=U5k0OvFOZB81a7H-UP7Q8A Persons Joshua Brody Title Preliminary Analysis Of Data Evaluating Investigational Epcoritamab (Duobody® Cd3xcd20) Combination Demonstrates 95% Overall Response Rate In Patients With Previously Untreated Follicular Lymphoma Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 2/06/24 Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet Business Wire Country/Territory United States Date 2/06/24 URL ct.moreover.com/?a=53962313260&p=1gw&v=1&x=zbAFSmHAQWxhswmAb5vmLg Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet InvestorsObserver Country/Territory United States Date 2/06/24 URL ct.moreover.com/?a=53962283671&p=1gw&v=1&x=hSgT1ZG3bf_dIZzR9u_3vQ Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet Finanzen.net Country/Territory Germany Date 2/06/24 URL ct.moreover.com/?a=53962280439&p=1gw&v=1&x=Gsg-AiHhyIplq4Im-fFA0A Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet ADVFN UK Country/Territory United Kingdom Date 2/06/24 URL ct.moreover.com/?a=53962280588&p=1gw&v=1&x=JhD-Sq8BEAkJ1mAH6JqGOg Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet Yahoo! Finanzas Country/Territory United States Date 2/06/24 URL ct.moreover.com/?a=53962307723&p=1gw&v=1&x=YGpp7FxZm2FmnFPcEJwd6w Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet Yahoo! Finance Country/Territory United States Date 2/06/24 URL ct.moreover.com/?a=53962316401&p=1gw&v=1&x=HJ_T2u_VUYY7wavjI9w4sg Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet APNews.com Country/Territory United States Date 2/06/24 URL ct.moreover.com/?a=53962304621&p=1gw&v=1&x=-7srtt81PZjTgQLJwJop5g Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody(TM) CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet Stockwatch Country/Territory Canada Date 2/06/24 URL ct.moreover.com/?a=53962300981&p=1gw&v=1&x=kgSEo0UNK1exvLdkd5GKdg Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet ADVFN US Country/Territory United States Date 2/06/24 URL ct.moreover.com/?a=53962301633&p=1gw&v=1&x=VHpAF9NiHCph7ko3gVqhuA Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet Crwe World Country/Territory United States Date 2/06/24 URL ct.moreover.com/?a=53962309742&p=1gw&v=1&x=D65He978DUVhR0Wcw1V0-Q Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet GlobeNewswire Country/Territory United States Date 2/06/24 URL ct.moreover.com/?a=53962301307&p=1gw&v=1&x=AqLzRpSxvH5IunwTWfgSIw Persons Joshua Brody Title Genmab A/S: Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet FinanzNachrichten.de Country/Territory Germany Date 2/06/24 URL ct.moreover.com/?a=53962309105&p=1gw&v=1&x=xS983CCzk8udVCl6FXz2Ug Persons Joshua Brody Title Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma Media name/outlet GlobeNewswire - English Country/Territory United States Date 2/06/24 Persons Joshua Brody